Dishman Carbogen Amcis Limited

DCAL

INE385W01011

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 03:31:11 16/01/2026 pm IST			5-day change	1st Jan Change
254.08 ^INR	-0.01%		-1.92%	+2.62%

27/12	Dishman Carbogen Amcis Limited Approves Issue of Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures Aggregating Up to INR 500 Million	CI
23/12	Dishman Carbogen Amcis to consider fund raising via NCDs	RE

Dishman Carbogen Amcis Limited Announces Cessation of Subir Kumar Das as Independent Director, Effective 15 December, 2024

Published on 12/14/2024 at 06:31 pm IST

S&P Capital IQ

Dishman Carbogen Amcis Limited

-0.01%

Dishman Carbogen Amcis Limited announced that the second and final term of Mr. Subir Kumar Das as an Independent Director has been completing on 14 December, 2024 and consequently cease to be Director of the Company with effect from 15 December, 2024.

Latest news about Dishman Carbogen Amcis Limited

27/12	Dishman Carbogen Amcis Limited Approves Issue of Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures Aggregating Up to INR 500 Million	CI
23/12	Dishman Carbogen Amcis to consider fund raising via NCDs	RE
05/11	Dishman Carbogen Amcis Limited, Q2 2026 Earnings Call, Nov 05, 2025
04/11	Dishman Carbogen Amcis Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
26/25/26	Dishman Carbogen Amcis receives EIR from US FDA indicating inspection closure	RE
13/25/13	Dishman Carbogen Amcis Limited, Q1 2026 Earnings Call, Aug 13, 2025
13/25/13	Dishman Carbogen Amcis Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
27/25/27	Dishman Carbogen Amcis Limited Announces the Demise of Shri Janmejay R. Vyas, Chairman & Non-Executive Director on May 27, 2025	CI
22/25/22	Dishman Carbogen Amcis Limited, Q4 2025 Earnings Call, May 22, 2025
22/25/22	Dishman Carbogen Amcis Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI
21/25/21	Dishman Carbogen Amcis Says Subsidiary Awarded Drug Manufacturing License From Chinese NMPA	RE
10/25/10	Dishman Carbogen's Shanghai Unit Gets Drug Manufacturing License	MT
09/25/09	Dishman Carbogen Amcis Says Unit Receives Drug Manufacturing License From NMPA For Shanghai Site	RE
01/25/01	Dishman Carbogen Amcis Limited Announces Resignations of Independent Directors	CI
26/25/26	Dishman Carbogen Amcis Raises INR500 Million Through Allotment of Debentures	MT
25/25/25	Dishman Carbogen Arm Gets French GMP Certification for Saint-Beauzire, France Site	MT
20/25/20	Dishman Carbogen Amcis Subsidiary Receives GMP Compliance Certificate for France Site	MT
19/25/19	Dishman Carbogen Amcis's unit Gets GMP Compliance Certificate For Saint-Beauzire Site	RE
13/25/13	Dishman Carbogen Amcis Gets Board for Up To INR500 Million Debenture Issue	MT
12/25/12	Dishman Carbogen Amcis Approves Issue Of Debentures Up To 500 Million Rupees	RE
07/25/07	Dishman Carbogen Amcis To Consider And Approve Proposal Of Fund Raising	RE
13/25/13	Dishman Carbogen Amcis Turns to Profit in Fiscal Q3	MT
13/25/13	Dishman Carbogen Amcis Limited, Q3 2025 Earnings Call, Feb 13, 2025
12/25/12	Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
04/25/04	Dishman Carbogen Amcis Limited Approves Appointment of Kulin N. Shah as an Independent Director	CI

Chart Dishman Carbogen Amcis Limited

Duration

Period

DCAL: Dynamic Chart

Company Profile

Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.

Employees

1,106

Sector

Pharmaceuticals

Calendar

06/02 - Q3 2026 Earnings Release (Projected)

More about the company